Literature DB >> 27423414

miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease.

Sylvia Hartmann1, Claudia Döring2, Claudio Agostinelli3, Soo-Jeong Portscher-Kim2, Silvia Lonardi4, Luisa Lorenzi4, Fabio Fuligni3, Daniel Martinez5, Jay Mehta6, Anita Borges6, Holger Hackstein7, Stefan Kippenberger8, Pier Paolo Piccaluga3, Ingrid Simonitsch-Klupp9, José Cabeçadas10, Elias Campo5, Fabio Facchetti4, Stefano A Pileri11, Martin-Leo Hansmann2.   

Abstract

Follicular dendritic cell (FDC) sarcomas are rare mesenchymal tumours, which are fatal in 20% of the patients and usually occur in secondary lymphoid organs or extranodal localizations. Due to the rareness of these tumours, only few studies have been conducted on molecular level. In the present study, we performed microRNA (miRNA) profiling of 31 FDC sarcomas and identified two subgroups, one with high miRNA expression and the other group with low miRNA expression levels. The first group showed a strong similarity to fibroblasts and myopericytomas, whereas the second group was more closely related to FDCs from Castleman's disease. Both groups showed important differences compared with myeloid-derived dendritic cells, confirming mesenchymal origin of FDCs and their derived sarcomas. The two FDC sarcoma groups did not differ on morphological grounds, mitotic activity or BRAF mutation status. However, patients of group I presented a tendency to a shorter overall survival and more frequent podoplanin expression by immunohistochemistry. The importance of these newly recognized FDC sarcoma subgroups in terms of clinical behaviour and therapeutic implications should be assessed in a larger cohort in future studies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; Cell of origin; Follicular dendritic cell sarcoma; Follicular dendritic cells; Podoplanin; miRNA profiling

Mesh:

Substances:

Year:  2016        PMID: 27423414     DOI: 10.1016/j.ejca.2016.06.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Authors:  Fabio Facchetti; Stefano Aldo Pileri; Luisa Lorenzi; Valentina Tabanelli; Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-07-10       Impact factor: 4.064

Review 2.  Follicular dendritic cell sarcoma presenting as a thyroid mass: an unusual case report and literature review.

Authors:  Ting Zhang; Liang He; Zhihong Wang; Wenwu Dong; Wei Sun; Ping Zhang; Hao Zhang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 3.  Follicular dendritic cell sarcoma.

Authors:  Fabio Facchetti; Matteo Simbeni; Luisa Lorenzi
Journal:  Pathologica       Date:  2021-10

Review 4.  A Cytological Review of Follicular Dendritic Cell-Derived Tumors with Emphasis on Follicular Dendritic Cell Sarcoma and Unicentric Castleman Disease.

Authors:  José A Jiménez-Heffernan; Cristina Díaz Del Arco; Magdalena Adrados
Journal:  Diagnostics (Basel)       Date:  2022-02-04

5.  Profiles of genomic alterations in primary esophageal follicular dendritic cell sarcoma: A case report.

Authors:  Wei Ren; Qi Sun; Pu-Yuan Wu; Bin Huang; Ju Yang; Jing Yan; Bao-Rui Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.